An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients

British Journal of Haematology

Volumn 156, Issue 4, 2012, Pages 481-489

  Cortelezzi, Agostino ^a,b   Gritti, Giuseppe ^b   Laurenti, Luca ^c   Cuneo, Antonio ^d   Ciolli, Stefania ^e   di Renzo, Nicola ^f   Musto, Pellegrino ^g   Mauro, Francesca R ^h   Cascavilla, Nicola ⁱ   Falchi, Lorenzo ^j   Zallio, Francesco ^k   Callea, Vincenzo ^l   Maura, Francesco ^a   Martinelli, Sara ^d   Piciocchi, Alfonso ^m   Reda, Gianluigi ^a   Foà, Robin ^h  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f VITO FAZZI HOSPITAL   (Italy)

^g REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^j S MARIA HOSPITAL   (Italy)

^k C Arrigo Children's Hospital   (Italy)

^l BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^m GIMEMA Data Centre   (Italy)

more..

Author keywords

Alemtuzumab; Chronic lymphocytic leukaemia; Infection; Monoclonal antibodies

Indexed keywords

ALEMTUZUMAB; DEXAMETHASONE; FLUDARABINE;

ADULT; AGED; AGING; ANEMIA; ARTICLE; BACTERIAL PNEUMONIA; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG FATALITY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; INJECTION SITE REACTION; ITALY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; SOFT TISSUE INFECTION; SPLEEN SIZE; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; ITALY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84856272135     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08965.x     Document Type: Article

References (30)

1. Bezares, R.F., Stemelin, G., Diaz, A., Argentieri, D., Zubiaur, E.L., Garay, G., Bartomioli, M., Ryser, R. & Milone, G. (2011) Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis. Leukaemia & Lymphoma, 52, 1936-1941.
2. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. & Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990-4997.
3. Cortelezzi, A., Pasquini, M.C., Sarina, B., Bertani, G., Grifoni, F., Colombi, M. & Lambertenghi Deliliers, G. (2005) A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with chemotherapy-refractory chronic lymphocytic leukemia. Haematologica, 90, 410-412.
4. Cortelezzi, A., Pasquini, M.C., Gardellini, A., Gianelli, U., Bossi, A., Reda, G., Sarina, B., Musto, P., Barcellini, W., Neri, A. & Deliliers, G.L. (2009) Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia, 23, 2027-2033.
5. Danese, M.D., Griffiths, R.I., Gleeson, M., Satram-Hoang, S., Knopf, K., Mikhael, J. & Reyes, C. (2011) An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia. Blood, 117, 3505-3513.
6. Fiegl, M., Falkner, A., Hopfinger, G., Brugger, S., Zabernigg, A., Bauer, F., Haslbauer, F., Demirtas, D., Grossschmidt, P., Tatzreiter, G., Gastl, G. & Greil, R. (2006) Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. Cancer, 107, 2408-2416.
7. Fiegl, M., Erdel, M., Tinhofer, I., Brychtova, Y., Panovska, A., Doubek, M., Eigenberger, K., Fonatsch, C., Hopfinger, G., Muhlberger, H., Zabernigg, A., Falkner, F., Gastl, G., Mayer, J. & Greil, R. (2010) Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. Annals of Oncology, 21, 2410-2419.
8. Gribben, J.G. (2010) Chronic lymphocytic leukemia: planning for an aging population. Expert Review of Anticancer Therapy, 10, 1389-1394.
9. Gribben, J.G. & Hallek, M. (2009) Rediscovering alemtuzumab: current and emerging therapeutic roles. British Journal Haematology, 144, 818-831.
10. Gritti, G., Reda, G., Maura, F., Piciocchi, A., Baldini, L., Molica, S., Neri, A. & Cortelezzi, A. (2011) Low dose alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia patients. Leukaemia & Lymphoma, in press (doi:).
11. Hallek, M. & Pflug, N. (2011) State of the art treatment of chronic lymphocytic leukaemia. Blood Reviews, 25, 1-9.
12. Hillmen, P., Skotnicki, A.B., Robak, T., Jaksic, B., Dmoszynska, A., Wu, J., Sirard, C. & Mayer, J. (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology, 25, 5616-5623.
13. Keating, M.J., Flinn, I., Jain, V., Binet, J.L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B. & Rai, K.R. (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood, 99, 3554-3561.
14. Keating, M., Coutre, S., Rai, K., Osterborg, A., Faderl, S., Kennedy, B., Kipps, T., Bodey, G., Byrd, J.C., Rosen, S., Dearden, C., Dyer, M.J. & Hillmen, P. (2004) Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma, 4, 220-227.
15. Laurenti, L., Piccioni, P., Tarnani, M., Efremov, D.G., Fiorini, A., Garzia, M. & Sica, S. (2005) Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience. Haematologica, 90, 1143-1145.
16. Lozanski, G., Heerema, N.A., Flinn, I.W., Smith, L., Harbison, J., Webb, J., Moran, M., Lucas, M., Lin, T., Hackbarth, M.L., Proffitt, J.H., Lucas, D., Grever, M.R. & Byrd, J.C. (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood, 103, 3278-3281.
17. Lundin, J., Kimby, E., Bjorkholm, M., Broliden, P.A., Celsing, F., Hjalmar, V., Mollgard, L., Rebello, P., Hale, G., Waldmann, H., Mellstedt, H. & Osterborg, A. (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood, 100, 768-773.
18. Morrison, V.A. (2010) Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol, 23, 145-153.
19. Nosari, A., Montillo, M. & Morra, E. (2004) Infectious toxicity using alemtuzumab. Haematologica, 89, 1415-1419.
20. Nosari, A., Tedeschi, A., Ricci, F. & Montillo, M. (2008) Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab. Haematologica, 93, e30-e31.
21. Osterborg, A., Fassas, A.S., Anagnostopoulos, A., Dyer, M.J., Catovsky, D. & Mellstedt, H. (1996) Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. British Journal Haematology, 93, 151-153.
22. Osterborg, A., Dyer, M.J., Bunjes, D., Pangalis, G.A., Bastion, Y., Catovsky, D. & Mellstedt, H. (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 15, 1567-1574.
23. Osterborg, A., Foa, R., Bezares, R.F., Dearden, C., Dyer, M.J., Geisler, C., Lin, T.S., Montillo, M., van Oers, M.H., Wendtner, C.M. & Rai, K.R. (2009) Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia, 23, 1980-1988.
24. Pendino, G.M., Mariano, A., Surace, P., Caserta, C.A., Fiorillo, M.T., Amante, A., Bruno, S., Mangano, C., Polito, I., Amato, F., Cotichini, R., Stroffolini, T. & Mele, A. (2005) Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology, 41, 1151-1159.
25. Pettitt, A.R., Matutes, E. & Oscier, D. (2006) Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia, 20, 1441-1445.
26. R Development Core Team (2009). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org.
27. Rai, K.R., Freter, C.E., Mercier, R.J., Cooper, M.R., Mitchell, B.S., Stadtmauer, E.A., Santabarbara, P., Wacker, B. & Brettman, L. (2002) Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. Journal of Clinical Oncology, 20, 3891-3897.
28. Stilgenbauer, S. & Dohner, H. (2002) Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. New England Journal of Medicine, 347, 452-453.
29. Stilgenbauer, S., Zenz, T., Winkler, D., Buhler, A., Schlenk, R.F., Groner, S., Busch, R., Hensel, M., Duhrsen, U., Finke, J., Dreger, P., Jager, U., Lengfelder, E., Hohloch, K., Soling, U., Schlag, R., Kneba, M., Hallek, M. & Dohner, H. (2009) Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology, 27, 3994-4001.
30. Zenz, T., Habe, S., Denzel, T., Mohr, J., Winkler, D., Buhler, A., Sarno, A., Groner, S., Mertens, D., Busch, R., Hallek, M., Dohner, H. & Stilgenbauer, S. (2009) Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood, 114, 2589-2597.